Browsing by Author "Asfuroğlu P."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    ERS International Virtual Congress 2021: Highlights from the Turkish Thoracic Society Early Career Members
    (AVES, 2022) Yumrukuz Şenel M.; Karadoğan D.; Vardaloğlu I.; Develi E.; Çelik S.; Hızal M.; Özseren B.; Öncel A.; Can İ.; Hürsoy N.; Uyar K.; Karakaş F.G.; Er B.; Asfuroğlu P.; Gürsoy T.R.; Eyüboğlu T.Ş.; Çakır E.P.; Ademhan D.; Karaoğlanoğlu S.; Emiralioğlu N.; Öztürk N.A.A.; Marim F.; Güçlü Ö.A.; Çetin N.; Topçu D.Ö.; Çelik P.; Akgün M.
    This review aimed to highlight some important points derived from the presentations of the European Respiratory Society 2021 Virtual International Congress by a committee formed by the Early Career Task Group of the Turkish Thoracic Society. We summarized a wide range of topics including current developments of respiratory diseases and provided an overview of important and striking topics of the congress. Our primary motivation was to give some up-to-date information and new developments discussed during congress especially for the pulmonologists who did not have a chance to follow the congress. This review also committed an opportunity to get an overview of the newest data in the diverse fields of respiratory medicine such as post-coronavirus disease 2019, some new interventional and technologic developments related to respiratory health, and new treatment strategies. © Author(s).
  • No Thumbnail Available
    Item
    Patients with cystic fibrosis who could not receive the CFTR modulator treatment: What did they lose in 1 year?
    (John Wiley and Sons Inc, 2023) Uytun S.; Cinel G.; Eryılmaz Polat S.; Özkan Tabakçı S.; Kiper N.; Yalçın E.; Ademhan Tural D.; Özsezen B.; Şen V.; Selimoğlu Şen H.; Ufuk Altıntaş D.; Çokuğraş H.; Kılınç A.A.; Başkan A.K.; Yazan H.; Çollak A.; Uzuner S.; Ünal G.; Yılmaz A.İ.; Çağlar H.T.; Damadoğlu E.; Irmak İ.; Demir E.; Kartal Öztürk G.; Bingöl A.; Başaran E.; Sapan N.; Canıtez Y.; Tana Aslan A.; Asfuroğlu P.; Harmancı K.; Köse M.; Hangül M.; Özdemir A.; Çobanoğlu N.; Özcan G.; Keskin Ö.; Yüksel H.; Özdoğan Ş.; Topal E.; Çaltepe G.; Can D.; Korkmaz Ekren P.; Kılıç M.; Emiralioğlu N.; Şişmanlar Eyüboğlu T.; Pekcan S.; Çakır E.; Özçelik U.; Doğru D.
    Background: Cystic fibrosis (CF) is an autosomal recessive disorder caused by CF transmembrane conductance regulator (CFTR) genetic variants. CFTR modulators improve pulmonary function and reduce respiratory infections in CF. This study investigated the clinical and laboratory follow-up parameters over 1 year in patients with CF who could not receive this treatment. Methods: This retrospective cohort study included 2018 and 2019 CF patient data from the CF registry of Turkey. Demographic and clinical characteristics of 294 patients were assessed, who had modulator treatment indications in 2018 but could not reach the treatment. Results: In 2019, patients younger than 18 years had significantly lower BMI z-scores than in 2018. During the 1-year follow-up, forced expiratory volumes (FEV1) and FEV1 z-scores a trend toward a decrease. In 2019, chronic Staphylococcus aureus colonization, inhaled antipseudomonal antibiotic use for more than 3 months, oral nutritional supplement requirements, and oxygen support need increased. Conclusions: Patients who had indications for modulator treatments but were unable to obtain them worsened even after a year of follow-up. This study emphasized the importance of using modulator treatments for patients with CF in our country, as well as in many countries worldwide. © 2023 Wiley Periodicals LLC.
  • No Thumbnail Available
    Item
    Factors associated with pulmonary function decline of patients in the cystic fibrosis registry of Turkey: A retrospective cohort study
    (John Wiley and Sons Inc, 2024) Emiralioğlu N.; Çakır B.; Sertçelik A.; Yalçın E.; Kiper N.; Şen V.; Altıntaş D.U.; Serbes M.; Çokuğraş H.; Kılınç A.A.; Başkan A.K.; Hepkaya E.; Yazan H.; Türel Ö.; Kafi H.M.; Yılmaz A.İ.; Ünal G.; Çağlar T.; Damadoğlu E.; Irmak İ.; Demir E.; Öztürk G.; Bingöl A.; Başaran E.; Sapan N.; Aslan A.T.; Asfuroğlu P.; Harmancı K.; Köse M.; Hangül M.; Özdemir A.; Tuğcu G.; Polat S.E.; Özcan G.; Gayretli Z.G.; Keskin Ö.; Bilgiç S.; Yüksel H.; Özdoğan Ş.; Topal E.; Çaltepe G.; Can D.; Ekren P.K.; Kılıç M.; Süleyman A.; Eyüboğlu T.Ş.; Cinel G.; Pekcan S.; Çobanoğlu N.; Çakır E.; Özçelik U.; Doğru D.
    Background: The decline in pulmonary function is a predictor of disease progression in patients with cystic fibrosis (CF). This study aimed to determine the decline rate of percent predicted forced expiratory volume in 1 s (ppFEV1) based on the data of the CF Registry of Turkey. The secondary aim was to investigate the risk factors related to the decline in ppFEV1. Methods: A retrospective cohort study of CF patients over 6 years old, with pulmonary function data over at least 2 years of follow-up was extracted from the national CF registry for years 2017–2019. Patients were classified according to disease severity and age groups. Multivariate analysis was used to predict the decline in ppFEV1 and to investigate the associated risk factors. Results: A total of 1722 pulmonary function test results were available from 574 patients over the study period. Mean diagnostic age was older and weight for age, height for age, and body mass index z scores were significantly lower in the group of ppFEV1 < 40, while chronic Pseudomonas aeruginosa (p <.001) and mucoid P. aeruginosa colonization (p <.001) were significantly higher in this group (p <.001). Overall mean annual ppFEV1 decline was −0.97% (95% confidence interval [CI] = −0.02 to −1.92%). The mean change of ppFEV1 was significantly higher in the group with ppFEV1 ≥ 70 compared with the other (ppFEV1 < 40 and ppFEV1: 40–69) two groups (p =.004). Chronic P. aeruginosa colonization (odds ratio [OR] = 1.79 95% CI = 1.26–2.54; p =.01) and initial ppFEV1 ≥ 70 (OR = 2.98 95% CI = 1.06-8.36), p =.038) were associated with significant ppFEV1 decline in the whole cohort. Conclusions: This data analysis recommends close follow-up of patients with normal initial ppFEV1 levels at baseline; advocates for early interventions for P. aeruginosa; and underlines the importance of nutritional interventions to slow down lung disease progression. © 2024 Wiley Periodicals LLC.